Why do patients fail HIV therapy?

International Journal of Clinical Practice

Volumn 61, Issue 6, 2007, Pages 983-990

  Waters, L ^a   Nelson, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HLA B ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR PLUS EFAVIRENZ PLUS LAMIVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANEMIA; BODY FAT DISTRIBUTION; CD4+ T LYMPHOCYTE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LYMPHOCYTE COUNT; NAUSEA; PATIENT COMPLIANCE; PHARMACOGENOMICS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; RITONAVIR; TREATMENT FAILURE;

EID: 34248392975     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01383.x     Document Type: Review

References (81)

1. Smit C, Geskus R, Walker S et al., CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006 20 : 741 9.
2. Cassetti I, Madruga JVR, Suleiman JMAH et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 5 years in antiretroviral-naïve patients. Eighth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Francisco, CA, 2006.
3. Murphy R, da Silva B, McMillan F et al. Seven year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral-naive subjects. Program and Abstracts of the 10th EACS, 17-20 November 2005, Dublin, Ireland.
4. Gulick RM, Ribaudo HJ, Shikuma CM et al. for the AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004 350 : 1850 61.
5. Benzie AA, Bansi LK, Sabin C et al. Viral rebound in patients on antiretroviral therapy with viral suppression: association with extent of previous virological failure and time with viral suppression. 12th BHIVA. Brighton, UK, 29 March-1 April 2006 [Oral Abstract O9].
6. Lampe S, Gatell J, Staszewski S et al. Trends over time in initial virological failure of first HAART: 1996 to 2002. A joint cohort analysis of 4143 subjects. 12th Conference on Retroviruses and Opportunistic Infections (CROI), 22-25 February 2005. Boston, MA [Abstract 590].
7. Palella FJ Jr., Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 338 : 853 60.
8. Reisler RB, Han C, Burman WJ, Tedaldi EM, Ellen N, Neaton J. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003 34 : 379 86.
9. Lau B, Gange S, Moore R. Non-AIDS related mortality risk exceeds AIDS-related mortality among injecting drug users with CD4+ counts above 200 cells/mm3. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, Colerado, USA, 5-8 February 2006, CO [Abstract 29].
10. Mandalia S, Brettle R, Fisher M et al. Cause and time to treatment failure of HAART and cost of care in UK NPMS-HHC clinics, 1996-2002. HIV Med 2006 7 : 9 [Abstract No. O33].
11. Riddler SA, Haubrich R, Di Rienzo G et al. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV infection-ACTG 5142. XVI International AIDS Conference, 13-18 August 2006, Toronto, ON [Abstract THLB0204].
12. Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006 7 : 487 503.
13. Markowitz M, Hill-Zabala C, Lang J et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005 39 : 257 64.
14. Moyle G, Nelson M, Higgs C et al. A randomised open label comparative study of combivir plus efavirenz (2 class triple therapy) versus trizivir plus tenofovir (single class quadruple therapy) in initial therapy for HIV-1 infection. 44th Interscience Conference of Antimicrobial Agents and Chemotherapy, 30 October-2 November 2004, Washington, DC [Abstract H1131].
15. Latham V, Stebbing J, Mandalia S et al. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother 2005 56 : 186 9.
16. Gallant JE, Rodriguez AE, Weinberg W et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005 192 : 1921 30.
17. Khanlou H, Yeh V, Guyer B, Farthing C. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005 19 : 135 40.
18. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004, San Francisco, CA [Abstract 51].
19. Kearney BP, Sayre JR, Flaherty J, Chen SS, Kaul S, Cheng AK. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol 2005 45 : 1360 7.
20. Pruvost A, Negredo E, Benech H et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2005 49 : 907 14.
21. Tung MY, Mandalia S, Bower M, Gazzard B, Nelson M. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily. HIV Med 2005 6 : 151 4.
22. Leon A, Mallolas J, Martinez E et al. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. AIDS 2005 19 : 1695 7.
23. Maitland D, Moyle G, Hand J et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005 19 : 1183 8.
24. Podzamczer D, Ferrer E, Gatell JM et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther 2005 10 : 171 7.
25. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004 48 : 1089 95.
26. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004 18 : 2442 4.
27. Negredo E, Molto J, Burger D et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir based regimens despite undetectable viral load. AIDS 2004 18 : 459 63.
28. Negredo E, Puig J, Masmitja E, Molto J, Ruiz L, Clotet B. CD4 cell count changes after reduction of didanosine dosage in patients receiving standard doses of didanosine and tenofovir-based regimens. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October-November 2004, Washington, DC, 30 October-2 November [Abstract No. H561].
29. Bristol Myers Squibb - data on file.
30. Negredo E, Bonjoch A, Paredes R et al. Concurrent administration of tenofovir (TDF) and didanosine (ddI) compromises immunologic recovery in treatment-experienced patients. Results from the TORO studies. Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, 2004, 14-17 November [Abstract P3].
31. Martinez E, Milinkovic A, de Lazzari E et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet 2004 364 : 65 7.
32. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of The International AIDS Society-USA panel. JAMA 2006 296 : 827 43.
33. Little SJ, Dawson K, Hellmann NS, Richman DD, Frost SDW. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. Antivir Ther 2003 8 : S129 [Abstract 115].
34. Brenner B, Routy J-P, Quan Y et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004 18 : 1653 60.
35. Cong M, Bennett DE, Heneine W, García-Lerma JG. Fitness cost of drug resistance mutations is relative and is modulated by other resistance mutations: implications for persistence of transmitted resistance. Antivir Ther 2005 10 (Suppl. 1 S169 [Abstract 154].
36. Bennett D, Zaidi I, Heneine W et al. Prevalence of mutations associated with antiretroviral drug resistance among recently diagnosed persons with HIV, 1998-2000. 9th Conference on Retroviruses and Opportunistic Infections (CROI), 24-28 February 2002, Seattle, WA [Abstract 372].
37. Bennett D, McCormick L, Kline R et al. U.S. surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera. 12th Conference on Retroviruses and Opportunistic Infections (CROI), 22-25 February 2005, Boston, MA [Abstract 674].
38. Little SJ, May S, Hecht F et al. Increase in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia. Antivir Ther 2006 11 : S110 Abstract 97 2006 16 : 14 9.
39. Descamps D, Chaix ML, Andre P et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-nai ̈ ve chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005 38 : 545 52.
40. de Mendoza C, Rodriguez C, Colomina J et al. Resistance to non-nucleoside reverse transcriptase inhibitors and prevalence of HIV Type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 2005 41 : 1350 4.
41. Rinck G, Tatt ID, Murphy G et al. Trends in Transmitted Antiretroviral Drug Resistance in Men Who have Sex with Men Attending Genitourinary Medicine Clinics in England, Wales and Northern Ireland. Bangkok, Thailand : XV International AIDS Conference, 2004.
42. Blower S, Bodine E, Kahn J et al. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005 19 : 1 14.
43. Geretti AM. Antiretroviral resistance. J HIV Ther 2006 11 : 72 3.
44. Metzner KJ, Rauch P, Walter H et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconvertors. AIDS 2005 19 : 1819 25.
45. Metzner KJ. Detection and significance of minority quasispecies of drug-resistant HIV-1. J HIV Ther 2006 11 : 74 81.
46. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Int Med 2000 133 : 21 30.
47. Moyle G. The Assessing Patients' Preferred Treatments (APPT-1) study. Int J STD AIDS 2003 14 (Suppl. 1 34 6.
48. Munsiff A, Byrne S, Kadakia H, Boyle B. Once daily HAART achieves more durable virologic suppression than twice daily HAART in an ambulatory clinic, urban cohort. IAS Conference on HIV Pathogenesis and Treatment, Brazil, 24-27 July 2005 [Abstract no. WePe12.2C14].
49. Maitland D, Jackson A, Osorio J, Mandalia S, Moyle G, Gazzard B. Switching from twice daily (BID) abacavir (ABC) and lamivudine (3TC) to a fixed dose combination (FDC) of ABC/3TC taken once daily (QD) improves patient adherence and satisfaction with therapy. 8th Int Cong Drug Therapy HIV, Glasgow, 12-16 November 2006 [Abstract No. P170].
50. Rode R, Vrijens B, Niemi K, Wikstrom K, Heuser R, Podsadecki T. Differences in treatment compliance between lopinavir/ritonavir (LPV/r) given once (QD) versus twice (BID) daily do not affect virologic or immunologic outcomes. Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2005, Washington, DC [Abstract H-522].
51. Schrader S, Rahn LW, Emrich KG et al. Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir after switching from BID soft-gel capsules (SGC) to BID tablets. 8th Intl Workshop on Adverse Drug Reactions & Lipodystrophy in HIV, 24-26 September 2006, San Francisco, CA [Abstract 81].
52. Colfax G et al. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS 2007 21 : 239 40.
53. Colfax G et al. Club drugs and HIV infection: a review. Clin Infect Dis 2006 42 : 1463 9.
54. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006 43 : 411 7.
55. Malow RM, McPherson S, Klimas N et al. Alcohol & drug abuse: adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv 1998 49 : 1021 4.
56. Carrieri MP, Leport C, Protopopescu C et al. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006 41 : 477 85.
57. Dalessandro M, Conti CM, Gambi F et al. Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. J Clin Psychopharmacol 2007 27 : 58 61.
58. Yun L, Maravi M, Kobayashi J, Barton P, Davidson A. Antidepressant treatment improves adherence to ART among depressed HIV+ patients. J Acquir Immune Defic Syndr 2005 38 : 432 8.
59. Balfour L, Kowal J, Silverman A et al. A randomized controlled psycho-education intervention trial: improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care 2006 18 : 830 8.
60. O'Brien ME, Clark RA, Besch LC, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003 34 : 407 14.
61. Adapted from Munk. CPS Info Pack (suppl). POZ 1998.
62. Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006 20 : 711 8.
63. Eron J Jr., Yeni P, Gathe J Jr. et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006 368 : 476 82.
64. Combivir® [Zidovudine/Lamivudine] Tablets. Summary of Product Characteristics. Research Triangle Park, NC : GlaxoSmithKline, 2004.
65. DeJesus E, Herrera G, Teofilo E et al., CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004 39 : 1038 46.
66. Mallal S, Nolan D, Witt C et al. Association between the presence of HLA-B*5701, HLADR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002 359 : 727 32.
67. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006 43 : 99 102.
68. Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactions. Antivir Ther 2006 11 : L11 [Abstract No. 14].
69. Waters L, Gritz A, Maitland D, Nelson M. HLA-B5701 testing and abacavir hypersensitivity: a single centre experience. 8th International Congress on Drug Therapy in HIV Infection, November 12-16 2006, Glasgow, UK [Abstract PL9.2].
70. Gallant JE, Dejesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006 354 : 251 60.
71. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004 292 : 191 201.
72. Gilead 903E. IDRLW. San Francisco, CA, 2006.
73. Nelson M et al. The safety of tenofovir DF for the treatment of HIV infection: the first 4 years. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 2006 [Abstract 781].
74. Dubé MP, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine plus lamivudine or didanosine plus stavudine combined with nelfinavir, efavirenz, or both: A5005s, a substudy of ACTG 384. Antivir Ther 2002 7 : L18 [Abstract 27].
75. van der Valk M, Casula M, Weverling GJ et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther 2004 9 : 385 93.
76. Marín A, Casado J, Aranzabal L et al. Impact of the lipodystrophy syndrome in adherence and attitudes toward antiretroviral drugs. IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005 [Abstract No. WePe12.7C34].
77. Guaraldi G, Murri R, Orlando G et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 2003 4 : 99 106.
78. Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002 34 : 248 59.
79. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004 18 : 1029 36.
80. Moreno S, Domingo P, Perez Elias MJ et al. Identification and follow up of adverse events related to NRTI use that in the clinical practice cause their substitution for tenofovir DF (48 wk data from RECOVER cohort). IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005 [Abstract No. TuPe2.4C09].
81. Benn P, Sauret V, Cartledge J et al. Improvements in facial lipoatrophy at 48 weeks following substitution of a thymidine analog with tenofovir DF (TDF) or abacavir (ABC): a randomised, open-label study in persons with lipoatrophy and virological suppression on HAART. Program and Abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brazil [Abstract TuPeLB2.3C02].